Metabolomic Approaches in NASH and NAFLD R&D
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. It encompasses a spectrum of diseases that range from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Over the next decade, health experts expect NASH to become the leading cause of liver transplants.
Currently, there are no FDA-approved treatments for NASH. A diverse set of disease drivers including genetics, environmental cues, microbiota metabolism and lifestyle influences come together resulting in an uncertain natural history of NAFLD/NASH. The constellation of risk factors for NASH has spawned a remarkable array of targets, and there is a significant need to bring the most effective treatments through development and to patients quickly.
This webinar reviews applications of metabolomics in NASH research, including a recent study designed and carried out by Dr. Jamie Bates of Gilead Sciences. It also highlights new tools Metabolon currently offers NAFLD/NASH liver disease researchers.
- Technology overview
- Highlight the platform findings from Gilead’s Acetyl CoA Carboxylase inhibitor in a mouse model
- Metabolomics from discovery to the clinic
- Metabolomics as a translational resource
About Jamie Bates
Dr. Bates is a Senior Research Scientist at Gilead Sciences in Foster City, California. Her responsibilities as a senior scientist include supporting the clinical development of Gilead combination trials in NASH, leading project teams towards IND, and proposing/pitching new targets for NASH.
About Kari Wong
Kari Wong is a Senior Study Director at Metabolon. Dr. Wong earned her Ph.D in Molecular Metabolism and Nutrition from the University of Chicago.